

Docket No. 296551US0PCT



MAIL STOP PCT
IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Bertrand TAVITIAN, et al.

SERIAL NO: 10/593,256

GAU:

FILED: September 18, 2006

EXAMINER:

FOR: APTAMERS SELECTED FROM LIVE TUMOR CELLS AND THE USE THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon


Norman F. Oblon
Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar
Registration No. 34,423



SHEET 1 OF 1

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 296551US0PCT	SHEET 1 OF 1		SERIAL NO. 10/593,256
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Bertrand TAVITIAN, et al.					
		FILING DATE September 18, 2006			GROUP		
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/T.W./	AA	5 580 737	12/03/96	POLISKY, Barry et al.			
/T.W./	AB	2003/049644	03/13/03	RABIN, ROSS et al.			
/T.W./	AC	6 280 932	08/28/01	PARMA, David H. et al.			
/T.W./	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
/T.W./	AO	2004/011680	02/05/04	WO	YES		NO
/T.W./	AP	99/51777	10/14/99	WO	YES		NO
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
/T.W./	AW	ICHIHARA, Masatoshi et al., "RET and neuroendocrine tumors", Cancer Letters, Vol. 204, No. 2, Pages 197-211, 2004.					
/T.W./	AX	CHEN, Chi-hong B. et al., "Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3", Proceedings of The National Academy of Sciences of The United States of America, Vol. 100, No. 16, Pages 9226-9231, 2003.					
	AY						
	AZ					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner /Teresa Wessendorf/				Date Considered 10/11/2010			

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.